SIRONA BIOCHEM Corporate Update April 2024

VANCOUVER, British Columbia, April 08, 2024 (GLOBE NEWSWIRE) -- Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (“Sirona” or the “Company”) provides the following update:

Dear shareholders,

We are pleased to provide an update on our recent milestones and strategic decisions shaping Sirona Biochem’s path forward.

AGM

Last week, during our Annual General Meeting (AGM), we successfully gained another year of backing for our management team. Although it's common for many shareholders to abstain from voting, we're pleased to report that we've received numerous messages from our shareholders expressing their support for our ongoing corporate strategy.

Financing

We have closed our financing well below its anticipated goal. The small cap marketplace in the Canadian market is very challenged at this time. Our past supporting brokers do not have the fund-raising capabilities of the past. Instead of dropping the financing share price we are in discussion with investment funds to assist with our financial needs. This includes funds based in Europe, North America, and Asia, linking future investments to our commercialization of GlycoProteMim^TM.

The commercialization of GlycoProteMim^TM offers substantial potential for financial returns, benefits from clinically validated technology, and has a relatively swift path to generating revenue.

We persist in exploring non-dilutive funding sources from France and Canada as our preferred financing option whenever feasible.

Branding of GlycoProteMim^TM (TFC-1326)

We have successfully selected the brand name for our anti-aging product. We will soon be proceeding with the formal trademark registration. The name will be made public closer to launch. Our cosmetic branding expert, based in Paris, is currently concentrating on developing brand messaging to establish this new product line as a premium offering in the anti-aging market.

Preparation for Commercialization of GlycoProteMim^TM

We are on track for a commercial launch of our first consumer products containing GlycoProteMim^TM in Europe and North America in early 2025 through our subsidiary, Sirona Laboratories, with plans to expand to other international markets afterward. Additionally, we've expanded our strategy to include the development of a second GlycoProteMim^TM-infused product. Our brand and marketing team is convinced that broadening our product range is essential for achieving the best market penetration and ensuring consumer satisfaction.